Shares in Clavis Pharma ASA soared on the Oslo Bors Tuesday, on news that it licensed its Phase II pancreatic cancer drug CP-4126 to Clovis Oncology Inc., for an up-front payment of $15 million, plus a potential $365 million in development, regulatory and sales-related milestones. (BioWorld Today)